Covid-19 roundup: No­vavax says vac­cine shows 'broad cross-re­ac­tiv­i­ty' against Omi­cron; France can­cels or­der on Mer­ck’s an­tivi­ral pill — re­port

No­vavax said Wednes­day that ini­tial da­ta sug­gest its Covid-19 vac­cine demon­strat­ed “broad cross-re­ac­tiv­i­ty against Omi­cron and oth­er cir­cu­lat­ing vari­ants” af­ter two dos­es — though neu­tral­iza­tion was around 4-fold low­er against Omi­cron com­pared to the orig­i­nal strain.

As a re­sult, the com­pa­ny says it’s work­ing on an Omi­cron-spe­cif­ic vac­cine and plans to launch clin­i­cal stud­ies in the first quar­ter of 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.